Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Optimal time of initiating adjuvant chemotherapy after curative surgery in colorectal cancer patients.

Kang KM, Hong KS, Noh GT, Oh BY, Chung SS, Lee RA, Kim KH.

Ann Coloproctol. 2013 Aug;29(4):150-4. doi: 10.3393/ac.2013.29.4.150. Epub 2013 Aug 29.

2.

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.

Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA.

J Clin Oncol. 2006 Oct 20;24(30):4888-94. Epub 2006 Oct 2.

3.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.

BMC Cancer. 2011 Aug 10;11:344. doi: 10.1186/1471-2407-11-344.

4.

Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.

Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B.

Eur J Cancer. 2010 Apr;46(6):1049-55. doi: 10.1016/j.ejca.2010.01.020.

PMID:
20138505
5.

[FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].

Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K, Nagawa H.

Gan To Kagaku Ryoho. 2011 Oct;38(10):1627-32. Japanese.

PMID:
21996957
6.

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer.

Jeong WK, Shin JW, Baek SK.

Ann Surg Treat Res. 2015 Sep;89(3):124-30. doi: 10.4174/astr.2015.89.3.124. Epub 2015 Aug 24.

7.

FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.

Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K, Nagawa H.

Oncology. 2011;80(1-2):84-91. doi: 10.1159/000328761. Epub 2011 Jun 13.

PMID:
21677451
8.

Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.

Mukai M, Okada K, Fukumitsu H, Yazawa N, Hoshikawa T, Tajima T, Hirakawa H, Ogoshi K, Makuuchi H.

Oncol Rep. 2009 Sep;22(3):621-9.

PMID:
19639213
9.

Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.

Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K; Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group.

Gastric Cancer. 2011 Aug;14(3):212-8. doi: 10.1007/s10120-011-0027-3. Epub 2011 Feb 19.

PMID:
21336855
10.

Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.

Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007046. doi: 10.1002/14651858.CD007046.pub2. Review.

PMID:
20091614
11.

Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.

Papadakou M, Xydakis E, Bonios M, Makropoulou E, Boukis C, Kakavoulis T, Karaliotas C, Panagos G.

J BUON. 2006 Jul-Sep;11(3):285-9.

PMID:
17309151
12.

Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.

Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group.

J Clin Oncol. 2003 Jun 15;21(12):2282-7.

PMID:
12805327
13.

Postoperative adjuvant chemotherapy in rectal cancer operated for cure.

Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD004078. doi: 10.1002/14651858.CD004078.pub2. Review.

PMID:
22419291
14.

Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer.

Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Nakamura M, Makuuchi H.

Oncol Rep. 2008 Dec;20(6):1521-6.

PMID:
19020736
15.

The effect of adjuvant chemotherapy on stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer.

Ha TK, Jung MS, Lee KH, Lee KG, Kwon SJ.

Cancer Res Treat. 2009 Mar;41(1):19-23. doi: 10.4143/crt.2009.41.1.19. Epub 2009 Mar 31.

17.

Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.

Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H.

Anticancer Res. 2006 Mar-Apr;26(2B):1425-32.

18.

Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis.

Rayson D, Urquhart R, Cox M, Grunfeld E, Porter G.

J Oncol Pract. 2012 Jul;8(4):253-9. doi: 10.1200/JOP.2012.000578.

19.

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.

Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology.

Oncology. 2013;84(1):14-21. doi: 10.1159/000342429. Epub 2012 Oct 16.

PMID:
23076023
20.

Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.

Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M.

Gastric Cancer. 2004;7(4):240-5.

PMID:
15616772
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk